Loading…
Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo
Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs...
Saved in:
Published in: | Frontiers in cellular and infection microbiology 2022-12, Vol.12, p.1074903 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03 |
---|---|
cites | cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03 |
container_end_page | |
container_issue | |
container_start_page | 1074903 |
container_title | Frontiers in cellular and infection microbiology |
container_volume | 12 |
creator | Li, Yali Li, Sheng Chen, Min Xiao, Jialing Fang, Hong |
description | Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against
both
and
.
A total of 20
strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against
were evaluated
the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The
antifungal activity of PP alone and in combination with azoles and AmB against
infections was evaluated by
survival assay.
The
results revealed that PP individually was ineffective against
(MIC>16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of
, respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone (
= 0.04).
In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against
; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of
infection larvae, compared with they are alone. The
and
data show that PP could enhance the activity of POS against
This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment. |
doi_str_mv | 10.3389/fcimb.2022.1074903 |
format | article |
fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16</doaj_id><sourcerecordid>36569209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</originalsourceid><addsrcrecordid>eNpVkdtqGzEQhkVpaUKaF-hF0QvYHUm7WummUEwPgUAvmlyL0clV8EqLtDa4T9-NnYZENyPN8H-D-Aj5yGAthNKfo0ujXXPgfM1g6DSIN-SSc9GvuFbq7Yv7Bblu7QGWMwBXWrwnF0L2UnPQl2T8fcyhblObk6MhxuBmWiKdjvWQctqPdMKx4BwoZk-n0tCVjH_LbmlsMeU20009TnNxxbl9ozmUWOqIudGU6SHNtZySp8ehfCDvIu5auH6qV-T--7e7zc_V7a8fN5uvtyvXSTWvpBNWWe0tE2A7J1lEIT2GEHsQPgyDhNBry6xG8IPUGBQX2gsvoPPegrgiN2euL_hgpppGrEdTMJlTo9Stwbr8eBdMdEIBhp5LcB3Tg5WcdSi17ryWnsmF9eXMmvZ2DN6FPFfcvYK-nuT0x2zLwehBQSf7BcDPAFdLazXE5ywD8-jSnFyaR5fmyeUS-vRy63PkvznxD5Ccnxk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><source>PubMed Central</source><creator>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</creator><creatorcontrib>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</creatorcontrib><description>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against
both
and
.
A total of 20
strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against
were evaluated
the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The
antifungal activity of PP alone and in combination with azoles and AmB against
infections was evaluated by
survival assay.
The
results revealed that PP individually was ineffective against
(MIC>16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of
, respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone (
= 0.04).
In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against
; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of
infection larvae, compared with they are alone. The
and
data show that PP could enhance the activity of POS against
This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</description><identifier>ISSN: 2235-2988</identifier><identifier>EISSN: 2235-2988</identifier><identifier>DOI: 10.3389/fcimb.2022.1074903</identifier><identifier>PMID: 36569209</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; antifungal ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; azoles ; Cellular and Infection Microbiology ; Cryptococcosis - drug therapy ; Cryptococcosis - microbiology ; Cryptococcus neoformans ; Fluconazole - pharmacology ; Fluconazole - therapeutic use ; Humans ; Itraconazole - pharmacology ; Itraconazole - therapeutic use ; Microbial Sensitivity Tests ; posaconazole ; pyrvinium pamoate ; synergistic effect ; Voriconazole - pharmacology</subject><ispartof>Frontiers in cellular and infection microbiology, 2022-12, Vol.12, p.1074903</ispartof><rights>Copyright © 2022 Li, Li, Chen, Xiao and Fang.</rights><rights>Copyright © 2022 Li, Li, Chen, Xiao and Fang 2022 Li, Li, Chen, Xiao and Fang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</citedby><cites>FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780465/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780465/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36569209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Yali</creatorcontrib><creatorcontrib>Li, Sheng</creatorcontrib><creatorcontrib>Chen, Min</creatorcontrib><creatorcontrib>Xiao, Jialing</creatorcontrib><creatorcontrib>Fang, Hong</creatorcontrib><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><title>Frontiers in cellular and infection microbiology</title><addtitle>Front Cell Infect Microbiol</addtitle><description>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against
both
and
.
A total of 20
strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against
were evaluated
the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The
antifungal activity of PP alone and in combination with azoles and AmB against
infections was evaluated by
survival assay.
The
results revealed that PP individually was ineffective against
(MIC>16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of
, respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone (
= 0.04).
In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against
; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of
infection larvae, compared with they are alone. The
and
data show that PP could enhance the activity of POS against
This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</description><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>antifungal</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>azoles</subject><subject>Cellular and Infection Microbiology</subject><subject>Cryptococcosis - drug therapy</subject><subject>Cryptococcosis - microbiology</subject><subject>Cryptococcus neoformans</subject><subject>Fluconazole - pharmacology</subject><subject>Fluconazole - therapeutic use</subject><subject>Humans</subject><subject>Itraconazole - pharmacology</subject><subject>Itraconazole - therapeutic use</subject><subject>Microbial Sensitivity Tests</subject><subject>posaconazole</subject><subject>pyrvinium pamoate</subject><subject>synergistic effect</subject><subject>Voriconazole - pharmacology</subject><issn>2235-2988</issn><issn>2235-2988</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkdtqGzEQhkVpaUKaF-hF0QvYHUm7WummUEwPgUAvmlyL0clV8EqLtDa4T9-NnYZENyPN8H-D-Aj5yGAthNKfo0ujXXPgfM1g6DSIN-SSc9GvuFbq7Yv7Bblu7QGWMwBXWrwnF0L2UnPQl2T8fcyhblObk6MhxuBmWiKdjvWQctqPdMKx4BwoZk-n0tCVjH_LbmlsMeU20009TnNxxbl9ozmUWOqIudGU6SHNtZySp8ehfCDvIu5auH6qV-T--7e7zc_V7a8fN5uvtyvXSTWvpBNWWe0tE2A7J1lEIT2GEHsQPgyDhNBry6xG8IPUGBQX2gsvoPPegrgiN2euL_hgpppGrEdTMJlTo9Stwbr8eBdMdEIBhp5LcB3Tg5WcdSi17ryWnsmF9eXMmvZ2DN6FPFfcvYK-nuT0x2zLwehBQSf7BcDPAFdLazXE5ywD8-jSnFyaR5fmyeUS-vRy63PkvznxD5Ccnxk</recordid><startdate>20221209</startdate><enddate>20221209</enddate><creator>Li, Yali</creator><creator>Li, Sheng</creator><creator>Chen, Min</creator><creator>Xiao, Jialing</creator><creator>Fang, Hong</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221209</creationdate><title>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</title><author>Li, Yali ; Li, Sheng ; Chen, Min ; Xiao, Jialing ; Fang, Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>antifungal</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>azoles</topic><topic>Cellular and Infection Microbiology</topic><topic>Cryptococcosis - drug therapy</topic><topic>Cryptococcosis - microbiology</topic><topic>Cryptococcus neoformans</topic><topic>Fluconazole - pharmacology</topic><topic>Fluconazole - therapeutic use</topic><topic>Humans</topic><topic>Itraconazole - pharmacology</topic><topic>Itraconazole - therapeutic use</topic><topic>Microbial Sensitivity Tests</topic><topic>posaconazole</topic><topic>pyrvinium pamoate</topic><topic>synergistic effect</topic><topic>Voriconazole - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Yali</creatorcontrib><creatorcontrib>Li, Sheng</creatorcontrib><creatorcontrib>Chen, Min</creatorcontrib><creatorcontrib>Xiao, Jialing</creatorcontrib><creatorcontrib>Fang, Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in cellular and infection microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Yali</au><au>Li, Sheng</au><au>Chen, Min</au><au>Xiao, Jialing</au><au>Fang, Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo</atitle><jtitle>Frontiers in cellular and infection microbiology</jtitle><addtitle>Front Cell Infect Microbiol</addtitle><date>2022-12-09</date><risdate>2022</risdate><volume>12</volume><spage>1074903</spage><pages>1074903-</pages><issn>2235-2988</issn><eissn>2235-2988</eissn><abstract>Cryptococcosis is a global invasive mycosis with high rates of morbidity and mortality, especially in AIDS patients. Its treatment remains challenging because of the limited antifungals and their unavoidable toxicity, and as such more efforts need to focus on the development of novel effective drugs. Previous studies have indicated that pyrvinium pamoate (PP) has individual and synergistic fungistatic effect. In this study, the effects of PP alone and in combination with azoles [fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS)] or amphotericin B (AmB) were evaluated against
both
and
.
A total of 20
strains collected from cryptococcal pneumonia and cryptococcal meningitis were studied. The effects of PP alone, PP-azoles and PP-AmB interactions against
were evaluated
the microdilution chequerboard technique, adapted from broth microdilution method according to the CLSI M27-A4. The
antifungal activity of PP alone and in combination with azoles and AmB against
infections was evaluated by
survival assay.
The
results revealed that PP individually was ineffective against
(MIC>16 μg/ml). Nevertheless, the synergistic effects of PP with ITR, VOR, POS, FLU or AmB was observed in 13 (65.0%, FICI 0.188-0.365), 3 (15.0%, FICI 0.245-0.301), 19 (95.0%, FICI 0.188-0.375), 7 (35.0%, FICI 0.188-0.375), and 12(60.0%, FICI 0.281-0.375) strains of
, respectively. There was no antagonism. The survival rates of larvae treated with PP (3.33%) showed almost no antifungal effective, but the larvae survival rates improved when PP combined with AmB (35% vs. 23.33%), FLU (40% vs. 25%), ITR (48.33% vs. 33.33%), VOR (48.33% vs. 53.33%) and POS (56.67% vs. 36.67%) comparison with AmB or azoles alone, and statistical significance was observed when PP combined with POS versus POS alone (
= 0.04).
In summary, the preliminary results indicated the potential of PP in reduction the MICs of azoles and AmB, also itself against
; the combination of PP with AMB, FLU, ITR, VOR and POS improve the survival rates of
infection larvae, compared with they are alone. The
and
data show that PP could enhance the activity of POS against
This study contributes with data of PP in combination with classical drugs of choice for cryptococcosis treatment.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36569209</pmid><doi>10.3389/fcimb.2022.1074903</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2235-2988 |
ispartof | Frontiers in cellular and infection microbiology, 2022-12, Vol.12, p.1074903 |
issn | 2235-2988 2235-2988 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_fc380ae5260c4197b6214a6994d96d16 |
source | PubMed Central |
subjects | Amphotericin B - pharmacology Amphotericin B - therapeutic use antifungal Antifungal Agents - pharmacology Antifungal Agents - therapeutic use azoles Cellular and Infection Microbiology Cryptococcosis - drug therapy Cryptococcosis - microbiology Cryptococcus neoformans Fluconazole - pharmacology Fluconazole - therapeutic use Humans Itraconazole - pharmacology Itraconazole - therapeutic use Microbial Sensitivity Tests posaconazole pyrvinium pamoate synergistic effect Voriconazole - pharmacology |
title | Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A43%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergistic%20effect%20of%20pyrvinium%20pamoate%20and%20posaconazole%20against%20Cryptococcus%20neoformans%20in%20vitro%20and%20in%20vivo&rft.jtitle=Frontiers%20in%20cellular%20and%20infection%20microbiology&rft.au=Li,%20Yali&rft.date=2022-12-09&rft.volume=12&rft.spage=1074903&rft.pages=1074903-&rft.issn=2235-2988&rft.eissn=2235-2988&rft_id=info:doi/10.3389/fcimb.2022.1074903&rft_dat=%3Cpubmed_doaj_%3E36569209%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-6c3b8b9db130b4c61fa36daeef503de7760e59b1b9a0d769ae8239d3d304ddb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36569209&rfr_iscdi=true |